Comparative Pharmacology
Head-to-head clinical analysis: ALSUMA versus ZOMIG ZMT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALSUMA versus ZOMIG ZMT.
ALSUMA vs ZOMIG-ZMT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction by cleaving SNAP-25, a protein required for synaptic vesicle fusion.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial blood vessels, inhibits trigeminal nerve transmission, and reduces neurogenic inflammation.
0.5 mg intramuscularly every 4 weeks
2.5 mg orally at onset of migraine; may repeat after 2 hours if needed. Maximum 10 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life: 9-11 hours; clinically, steady-state achieved in ~2 days
Terminal elimination half-life is approximately 3 to 3.5 hours for zolmitriptan and its active metabolite N-desmethyl zolmitriptan has a similar half-life. This supports a typical dosing interval of at least 2 hours between doses.
Renal: 70% unchanged; Biliary/Fecal: 20% as metabolites; 10% other
Approximately 60-70% of the administered dose is excreted in urine, primarily as metabolites (active N-desmethyl zolmitriptan and inactive indoleacetic acid derivatives), with about 10-15% as unchanged drug. Fecal excretion accounts for about 20-30% of the dose.
Category C
Category C
Triptan Antimigraine
Triptan Antimigraine